The MESOMARK Assay, a blood test developed to monitor patients with mesothelioma–a form of cancer caused by asbestos exposure–is now available to physicians in the U.S..  The test, which can be used to help manage the care of patients with epitheloid or biphasic mesothelioma, requires only a blood sample to be taken from the patient. […]

Pre-clinical studies reported at the annual meeting of the American Association of Cancer Research on April 16, 2007 show that  the chemotherapy drug Onconase significantly inhibits tumor growth in non-small cell lung cancer and breast cancer. Onconase is also subject to an ongoing Phase IIIb study in malignant mesothelioma, a form of cancer linked to […]